Patients and transplant characteristics according to CD20 expression
| Factors . | No. of patients (%) . | P . | |
|---|---|---|---|
| CD20-negative . | CD20-positive . | ||
| Total | 67 | 58 | |
| Age group, y | .37 | ||
| Younger than 10 | 15 (22) | 22 (38) | |
| 10 < 20 | 9 (13) | 8 (14) | |
| 20 < 40 | 20 (30) | 13 (23) | |
| 40 < 50 | 12 (18) | 6 (10) | |
| Older than 50 | 11 (16) | 9 (16) | |
| Year of transplant | .62 | ||
| 1999-2002 | 17 (25) | 19 (33) | |
| 2003-2009 | 50 (75) | 39 (67) | |
| Gender | .36 | ||
| Male | 39 (58) | 29 (50) | |
| Female | 28 (42) | 29 (50) | |
| Remission status at HSCT | .45 | ||
| CR1 | 38 (57) | 29 (50) | |
| CR2 | 29 (43) | 29 (50) | |
| Patient CMV serostatus | .12 | ||
| Negative | 28 (43) | 32 (57) | |
| Positive | 37 (57) | 24 (43) | |
| Cytogenetics | |||
| BCR/ABL–positive | 29 (43) | 25 (43) | .90 |
| MLL-AF4–positive | 10 (14) | 0 | .01 |
| Other cytogenetic groups | .13 | ||
| Complex | 5 (8) | 5 (9) | |
| Hyperdiploid | 5 (8) | 3 (5) | |
| Hypodiploid | 4 (6) | 3 (5) | |
| Normal karyotype | 6 (9) | 11 (19) | |
| del 9p | 1 (2) | 2 (3) | |
| Other | 4 (6) | 4 (7) | |
| Not available | 3 (4) | 5 (9) | |
| White blood cell count | |||
| Less than 30 000/μL | 32 (51) | 25 (48) | .77 |
| More than or equal to 30 000/μL | 31 (43) | 27 (52) | |
| Donor source | .45 | ||
| HLA matched, related | 22 (33) | 24 (41) | |
| Umbilical cord blood | 43 (64) | 31 (53) | |
| HLA matched, unrelated | 2 (3) | 3 (5) | |
| Conditioning intensity | .40 | ||
| Myeloablative | 54 (81) | 50 (86) | |
| Reduced intensity | 13 (19) | 8 (14) | |
| Factors . | No. of patients (%) . | P . | |
|---|---|---|---|
| CD20-negative . | CD20-positive . | ||
| Total | 67 | 58 | |
| Age group, y | .37 | ||
| Younger than 10 | 15 (22) | 22 (38) | |
| 10 < 20 | 9 (13) | 8 (14) | |
| 20 < 40 | 20 (30) | 13 (23) | |
| 40 < 50 | 12 (18) | 6 (10) | |
| Older than 50 | 11 (16) | 9 (16) | |
| Year of transplant | .62 | ||
| 1999-2002 | 17 (25) | 19 (33) | |
| 2003-2009 | 50 (75) | 39 (67) | |
| Gender | .36 | ||
| Male | 39 (58) | 29 (50) | |
| Female | 28 (42) | 29 (50) | |
| Remission status at HSCT | .45 | ||
| CR1 | 38 (57) | 29 (50) | |
| CR2 | 29 (43) | 29 (50) | |
| Patient CMV serostatus | .12 | ||
| Negative | 28 (43) | 32 (57) | |
| Positive | 37 (57) | 24 (43) | |
| Cytogenetics | |||
| BCR/ABL–positive | 29 (43) | 25 (43) | .90 |
| MLL-AF4–positive | 10 (14) | 0 | .01 |
| Other cytogenetic groups | .13 | ||
| Complex | 5 (8) | 5 (9) | |
| Hyperdiploid | 5 (8) | 3 (5) | |
| Hypodiploid | 4 (6) | 3 (5) | |
| Normal karyotype | 6 (9) | 11 (19) | |
| del 9p | 1 (2) | 2 (3) | |
| Other | 4 (6) | 4 (7) | |
| Not available | 3 (4) | 5 (9) | |
| White blood cell count | |||
| Less than 30 000/μL | 32 (51) | 25 (48) | .77 |
| More than or equal to 30 000/μL | 31 (43) | 27 (52) | |
| Donor source | .45 | ||
| HLA matched, related | 22 (33) | 24 (41) | |
| Umbilical cord blood | 43 (64) | 31 (53) | |
| HLA matched, unrelated | 2 (3) | 3 (5) | |
| Conditioning intensity | .40 | ||
| Myeloablative | 54 (81) | 50 (86) | |
| Reduced intensity | 13 (19) | 8 (14) | |